Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.

<h4>Background</h4>Overexpression of RRM1 and RRM2 has been associated with gemcitabine resistance. BRCA1 overexpression increases sensitivity to paclitaxel and docetaxel. We have retrospectively examined the effect of RRM1, RRM2 and BRCA1 expression on outcome to gemcitabine plus doceta...

Full description

Bibliographic Details
Main Authors: Ioannis Boukovinas, Chara Papadaki, Pedro Mendez, Miquel Taron, Dimitris Mavroudis, Anastasios Koutsopoulos, Maria Sanchez-Ronco, Jose Javier Sanchez, Maria Trypaki, Eustathios Staphopoulos, Vassilis Georgoulias, Rafael Rosell, John Souglakos
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2008-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19002265/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19002265/?tool=EBI

Similar Items